Leadership Team
The AIM Bio startup Toleris Biotherapeutics GmbH is led and advised by a very experienced team of science, medical and biotech experts. The project has won several highly competitive prices such as the m4 Award and EXIST Forschungstransfer grants as well as the jury and audience innovation awards of the 2022 German Biotechnology Days conference. Toleris collaborates with key opinion leaders Prof. Michael Levy (Harvard Medical School) and Prof. Friedemann Paul (Charité Berlin).
Image
Toleris AIM Bio pipeline overview
Toleris currently focuses on developing AIM Bios for neuroinflammatory autoimmune diseases such as multiple sclerosis (MS), MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorders (NMOSD) and Parkinson‘s disease, as well as for type 1 diabetes.
Image
